On September 11, 2020, Boehringer Ingelheim and Click Therapeutics announced a collaboration to develop and commercialize a prescription-based digital therapeutic (PDT) that provides a psychosocial intervention to help people diagnosed with schizophrenia achieve positive clinical outcomes. The goal is to help the users modify their behavior to reduce cognitive deficits and to improve social functioning, alone or in combination with an antipsychotic medication. The organizations will work together to achieve regulatory authorization from the U.S. Food and Drug Administration (FDA) and its international counterparts. The plan is to evaluate the PDT in a clinical study.
The PDT will . . .
Restricted Content
You must be an Elite member to view this resource.
